Anika Therapeutics logo

Anika TherapeuticsNASDAQ: ANIK

Profile

Sector:

Healthcare

Country:

United States

IPO:

03 May 1993

Next earnings report:

31 October 2024

Last dividends:

N/A

Next dividends:

N/A
$273.74 M
-57%vs. 3y high
58%vs. sector
-vs. 3y high
-vs. sector
-41%vs. 3y high
47%vs. sector
-63%vs. 3y high
33%vs. sector

Price

after hours | 4 min ago
$18.50-$6.18(-25.04%)

Dividend

No data over the past 3 years
$41.92 M$42.08 M
$41.92 M-$88.00 K

Analysts recommendations

Institutional Ownership

ANIK Latest News

Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates
zacks.com31 October 2024 Sentiment: NEGATIVE

Anika Therapeutics (ANIK) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of $0.30. This compares to loss of $0.45 per share a year ago.

Anika Reports Third Quarter 2024 Financial Results
globenewswire.com31 October 2024 Sentiment: NEUTRAL

Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds

Anika Therapeutics, Inc (ANIK) Q2 2024 Earnings Call Transcript
seekingalpha.com11 August 2024 Sentiment: POSITIVE

Anika Therapeutics, Inc (NASDAQ:ANIK ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations Cheryl Blanchard - President and Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Jim Sidoti - Sidoti & Company Harrison Parsons - Stephens Mike Petusky - Barrington Research Operator Good afternoon, ladies and gentlemen, and welcome to Anika's Second Quarter 2024 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Namaroff, Vice President, Investor Relations, ESG and Corp. Communications.

Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates
zacks.com08 August 2024 Sentiment: NEUTRAL

Anika Therapeutics (ANIK) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.19 per share a year ago.

Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs
globenewswire.com11 July 2024 Sentiment: POSITIVE

Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolio

Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
GlobeNewsWire27 February 2024 Sentiment: NEUTRAL

BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2023 financial results after the close of the market on Wednesday, March 13, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

New Strong Buy Stocks for December 14th
Zacks Investment Research14 December 2023 Sentiment: POSITIVE

MUSA, AVTX, ANIK, CARG and WES have been added to the Zacks Rank #1 (Strong Buy) List on December 14, 2023.

Anika Therapeutics, Inc. (ANIK) Q3 2023 Earnings Call Transcript
Seeking Alpha03 November 2023 Sentiment: POSITIVE

Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2023 Earnings Conference Call November 2, 2023 5:30 PM ET Company Participants Mark Namaroff - Vice President Investor Relations, ESG & Corporate Communications Cheryl Blanchard - President & Chief Executive Officer Mike Levitz - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Mike Petusky - Barrington Research George Sellers - Stephens Inc Jim Sidoti - Sidoti & Company Operator Good evening, ladies and gentlemen, and welcome to Anika's Third Quarter 2023 Earnings Conference Call. All participants' will be in a listen-only mode.

Down -20.42% in 4 Weeks, Here's Why You Should You Buy the Dip in Anika (ANIK)
Zacks Investment Research01 September 2023 Sentiment: POSITIVE

The heavy selling pressure might have exhausted for Anika (ANIK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

All You Need to Know About Anika (ANIK) Rating Upgrade to Buy
Zacks Investment Research31 August 2023 Sentiment: POSITIVE

Anika (ANIK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What type of business is Anika Therapeutics?

Anika Therapeutics, Inc. is an American manufacturer of drugs for preserving and restoring joints. The company was founded in 1992, with headquarters in Bedford, Massachusetts. Anika's proprietary technologies for modifying hyaluronic acid, which are protected by patents, allow for the effective alteration and adaptation of product properties. Anika's products include drugs for relieving joint pain; drugs, implants, surgical instruments for preserving and restoring joints; products for wound care, treatment of ENT diseases; ophthalmic drugs.

What sector is Anika Therapeutics in?

Anika Therapeutics is in the Healthcare sector

What industry is Anika Therapeutics in?

Anika Therapeutics is in the Drug Manufacturers - Specialty & Generic industry

What country is Anika Therapeutics from?

Anika Therapeutics is headquartered in United States

When did Anika Therapeutics go public?

Anika Therapeutics initial public offering (IPO) was on 03 May 1993

What is Anika Therapeutics website?

https://www.anika.com

Is Anika Therapeutics in the S&P 500?

No, Anika Therapeutics is not included in the S&P 500 index

Is Anika Therapeutics in the NASDAQ 100?

No, Anika Therapeutics is not included in the NASDAQ 100 index

Is Anika Therapeutics in the Dow Jones?

No, Anika Therapeutics is not included in the Dow Jones index

When was Anika Therapeutics the previous earnings report?

No data

When does Anika Therapeutics earnings report?

The next expected earnings date for Anika Therapeutics is 31 October 2024